NEW YORK, New York — OrbiMed Advisors, which has invested in Ohio companies Athersys Inc. and ViewRay, has raised $550 million for its latest health venture capital fund.
The company’s Caduceus Private Investments IV fund will be its largest-ever, surpassing its predecessor by $20 million, VentureWire reported.
OrbiMed plans to invest 60 percent of the fund in biotechnology, 30 percent in medical devices and 10 percent in diagnostics, and will back a total of 25 to 30 companies, according to VentureWire.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Last year, OrbiMed led a $25 million Series B round for Oakwood-based ViewRay, which is developing a device that uses MRIs to guide gamma rays to target cancerous tumors. OrbiMed lists Cleveland-based stem cell developer Athersys as one of its portfolio companies and OrbiMed General Partner Michael Sheffery sits on Athersys’ board.
Along with Frazier Healthcare Ventures‘ $600 million sixth fund and Essex Woodlands Health Ventures‘ $900 million eighth fund, OrbiMed’s latest fund is among the largest health care-only venture funds, VentureWire reported.
OrbiMed is headquartered in New York with offices in San Francisco, Shanghai and Mumbai.
A string of successful exits helped draw investors to OrbiMed’s latest fund, VentureWire said. Those exits include CoGenesys Inc., which sold to Teva Pharmaceutical Industries Ltd. in 2008; Cerexa Inc., acquired by Forest Laboratories Inc. in 2007; and Peninsula Pharmaceuticals Inc., bought by Johnson & Johnson in 2005.